Glenmark secures CDSCO panel nod for manufacturing, marketing acne drug Tazarotene

Published On 2021-03-28 05:30 GMT | Update On 2021-03-28 05:31 GMT

New Delhi: After reviewing the proposal for Tazarotene Lotion 0.045%, the Central Drugs Standard Control Organization (CDSCO) committee has given its nod to Glenmark Pharma for the manufacturing and marketing of the said formulation for the treatment of Acne.

The nod was given by the Subject Expert Committee (SEC) at its recent 56th SEC meeting (Dermatology & Allergy) held on 16.03.2021 at CDSCO HQ New Delhi.

The approval came after the firm presented the proposal for Tazarotene Lotion 0.045% for the treatment of Acne before the committee.

Also Read: Glenmark gets USFDA nod to Clindamycin Phosphate Gel to treat acne

Acne is a common skin problem that occurs when hair follicles become plugged with oil and skin cells, often causing whiteheads, blackheads or pimples to appear on the face, forehead, chest, upper back and shoulders. Depending on its severity, acne can cause emotional distress and scar the skin.

Tazarotene 0.05 %W/W is sold by Glenmark Pharma under the brand name TAZRET GEL 15GM to treat acne or pimples and psoriasis.

Tazarotene is a vitamin A derivative that acts by slowing down skin cell growth and blocking certain substances that cause skin inflammation (redness and swelling). This removes acne and eliminates scaling and thickening of the skin in psoriasis.

After detailed deliberation, the committee noted that the product is already approved internationally for the past several years. Tazarotene Cream and Gel 0.05% has been approved in India for many years.

Medical dialogues team had earlier reported that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application for ARAZLOTM (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older.

Responding to the proposal, the committee recommended for grant of permission for manufacturing and marketing of the drug product Tazarotene Lotion 0.045% for use in the treatment of Acne.

Also Read: Glenmark subsidiary gets Russian nod to market Ryaltris Nasal Spray

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medical Dialogues Team

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Glenmark secures CDSCO panel nod for manufacturing, marketing acne drug Tazarotene

Similar News

Sun Pharma net profit drops 20% to Rs 2,279 crore in Q1

Sandoz to acquire Just-Evotec Biologics EU SAS in-house development, manufacturing capabilities in France

Zydus Wellness sees exit of Head-R&D, Head-GDSO

Natco Pharma appoints TC Mallikarjun as Vice President - QC at Kothur Pharma Division

Ajanta Pharma Gets Relief in Erectile Dysfunction Drug Export Case, Penalty Set Aside

NPPA Panel Defers Biological E's Pneumonia Vaccine Price Exemption, Seeks Clarification

Aurobindo Pharma Acquires Lannett for Rs 2,185 Cr to Boost U.S. Presence, ADHD Line

Novo Nordisk Appoints Mike Doustdar as New CEO Amid Executive Reshuffle